Skip to main content
OpenTrials
Completed

NCT Number: NCT05506371

Effects of Azithromycin as an Adjunct to Scaling and Root Planning in the Treatment of Periodontitis

The growing interest in the possibilities of modulating macrophages in inflammatory diseases with therapeutic purpose has prompted the development of new approaches for the treatment of periodontitis.

This randomized add-on open clinical study evaluated the short-term effects of azithromycin (Az) as an adjunct to scaling and root planing (SRP) in patients with chronic periodontitis.

The investigators measured periodontal parameters, and collected gingival biopsies from patients with periodontitis (P group, n=50) before and 1 month after scaling and root planning (SRP group, n=25), after scaling and root planning with oral azithromycin administration (Az group, n=25), and from periodontally healthy individuals (H group, n=25). The last served as a reference group. Macrophage subpopulations were identified through immunohistochemistry as single positive CD68+ and CD163+ cells. The levels of M1-, and M2-related cytokines (IL1-β, IL-6, IL-10, TGF-β) assay in the tissue culture medium was provided by ELISA. The data were statistically analyzed by appropriate methods.

The null hypothesis tested was that L-arginine and L-ornithine have no influences on CD68+ and CD163+ Mφs densities.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–54 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Postgraduate Education for Dentists of Poltava State Medical University,

Poltava, 36011, Ukraine

About this study

Clinical periodontal examinations Periodontal parameters were evaluated at the pre-treatment stage (T0) and 4 weeks ±5 days after the completion of SRP. For all participants, sex and age were recorded, and periodontal parameters such periodontal pocket depth (PPD), clinical attachment loss (CAL), and bleeding on probing (BoP) were examined. All measurements were conducted by one calibrated examiner using a manual periodontal probe (0106.DT06.CP10, Den Tag, Italy). PPD and CAL were measured at six periodontal sites around each tooth (including the third molars) to the nearest 1 mm, and maximal values were taken into account. For H group participants the signs of gingival inflammation, probing depth exceeding 3 mm and BoP were exclude to insure periodontal health.

Periodontal therapy was comprised of home oral hygiene instructions and SRP. It was performed using ultrasonic, Gracey curettes and air-abrasive polishing. Measure for compliance control included counting pills and home hygiene checking.

Collection of gingival tissue samples For precise immunohistochemical study gingival biopsy samples, about 3x3 mm was excised following local anesthesia from all participants without any harm, during appropriate dental procedures. Biopsy from periodontitis-affected gingiva performed at pre-treatment (T0, P Group) and 4 weeks ±5 days after the completion of periodontal treatment, in the same or nearest points, from a single most severe clinical appropriate site around common dental and periodontal procedures such was tooth extraction due to caries complications, and gingivectomies. Biopsy from periodontally healthy patients were obtained during tooth extraction due to caries complications, wisdom teeth and orthodontic indications. After collection, the half of biopsies were fixed in a 4% formalin solution for 24 hours of fixation, dehydrated, and embedded in paraffin, and another half were prepared for cytokines assay.

Immunohistochemistry and antibodies Paraffin sections, 2-3 μm in thickness were deparaffinized and dehydrated. Heat-induced epitope retrieval in citrate buffer, pH 6, was performed by heating the slides in the microwave oven for 23 min, then allowed to cool, rinsed with phosphate-buffered saline (PBS), incubated with blocked reagent, rinsed, and incubated with mouse monoclonal CD68 macrophage antibodies (1:30, clone PG-M1, Diagnostic BioSystems, The Hague, The Netherlands) or anti-CD163 (1:100, clone 10D6, Diagnostic BioSystems, The Hague, The Netherlands). Then sections were stained with the 2-steps plus Mouse/Rabbit PolyVueTM HRP/DAB Detection System (Diagnostic BioSystems, The Hague, The Netherlands), and counterstained with Mayer's haemalaun. PBS was used as negative controls, the lymph node tissue - as a positive control.

Evaluation of immunohistochemical staining СD68+ and CD163+ macrophages were estimated by counting the number of the cells by light microscope in 400 times in intensive cell infiltrative areas, selected 5 regions from each slice, and all 5 counts were taken for further statistics. Immunopositive Mφs in the areas of cell infiltration were count, because of directly relation to the inflammation. The number of cells per 10 000 μm2 was calculated as immunopositive cell density. Photos and calculation were obtained using the light microscope Axio Lab.A1 (Carl Zeiss, Göttingen, Germany) (×400).

Tissue culturing Part of gingival tissue samples were cultured in a humidified incubator at 37 °C and in the presence of 5 % CO2. Biopsies were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10 % (vol/vol) fetal bovine serum (Gibco, Thermo Fisher Scientific, Gibco™, US), 1 % (vol/vol) penicillin-streptomycin (Gibco™, US), and 0.2 % (vol/vol) fungizone amphotericin B (Gibco™, US) during 48 h [16]. For culturing, each biopsy sample was placed in a separate well of Costar® 24-well Plates (Corning Incorporated - Life Sciences, Kennebunk, USA), containing 0,4 ml of supplemented DMEM. After incubation, the tissues were removed and culture media were centrifuged at 800 g and 4 °C.

Cytokine assay Cytokine assay in the tissue culture medium was provided by ELISA. IL1-β, IL-6, IL-10, and TGF-β concentrations were measured by commercially available kits (Vector Best, Novosibirsk, Russia, and MyBioSource, San Diego, USA). Cytokine concentrations were expressed as recommended by the manufacturer.

Statistical analysis Statistical analysis was performed using the Prism 5 software (GraphPad Software, San Diego, USA) by means of nonparametric (descriptive statistics, Wilcoxon matched-pairs signed-rank test - for comparison of dependent results, Mann-Whitney test - for independent groups; nonparametric ANOVA for multiple comparisons with post-hoc tests, and Spearmen correlation). CD68+/CD163+ ratio was assessed by inter-group comparisons and Spearman correlation checking. P values of <0.05 were considered statistically significant in all analyses. For descriptive statistics of cell numbers, the percentile ranges were also used because of non-normal variables distributions.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for healthy volunteers:

  • Presence of more than 20 teeth (for each tooth, the probing pocket depth ≤3 mm
  • Absence of clinical gingival inflammation at intact or reduced periodontium

Inclusion criteria

  • The presence of at least 15 natural teeth, at least 10 sites with the periodontal pocket depth (PPD) ≥4 mm, and/or clinical attachment loss of ≥4 mm at the same site, and satisfactory general health

Exclusion criteria

  • Taking antibiotics or anti-inflammatory medications within the previous 3 months
  • Periodontal therapy within the previous 6 months
  • Purulent exudation from periodontal pockets
  • Pregnancy or breastfeeding
  • Severe, uncontrolled (decompensated) diseases of the internal organs, or neuropsychiatric disorders
  • Other conditions that determined the patient's inability to understand the nature and possible consequences of the study

Treatment and study plan

Az+SRP

Drug

Azithromycin as an adjunct to scaling and root planning in the treatment of periodontitis

Other names: Azithromicyn group

SRP

Drug

Scaling and root planning (SRP) treatment of periodontitis

Other names: Periodontal conventional treatment group

No Interventions

Drug

Diagnostocs to confirm the healthy state of the gingiva

Other names: Reference/periodontal health group

Primary outcomes

  1. Change in clinical attachment loss (CAL)

    Time frame: The pre-treatment stage (T0) and 4 weeks ±5 days after the completion of SRP

    Mean CAL, measured at six periodontal sites around each tooth (including the third molars) to the nearest 1 mm

  2. Change in periodontal pocket depth (PPD)

    Time frame: The pre-treatment stage (T0) and 4 weeks ±5 days after the completion of SRP

    Mean periodontal pocket depth, measured at six periodontal sites around each tooth (including the third molars) to the nearest 1 mm

Secondary outcomes

  1. Change in bleeding on probing (BOP)

    Time frame: The pre-treatment stage (T0) and 4 weeks ±5 days after the completion of SRP

    The percentage of sites per patient with bleeding measured at six sites around each tooth (including the third molars)

  2. Change in density of CD68+ macrophages

    Time frame: The pre-treatment stage (T0) and 4 weeks ±5 days after the completion of SRP

    The number of single-immunopositive macrophages per 10 000 μm2 was calculated as cell density in biopsy from periodontitis-affected gingiva

  3. Change in density of CD163+ macrophages

    Time frame: The pre-treatment stage (T0) and 4 weeks ±5 days after the completion of SRP

    The number of single-immunopositive macrophages per 10 000 μm2 was calculated as cell density in biopsy from periodontitis-affected gingiva

  4. Change in mean level of IL1-β in periodontitis-affected gingiva

    Time frame: The pre-treatment stage (T0) and 4 weeks ±5 days after the completion of SRP

    The mean level of IL1-β in the tissue culture medium, obtained from the same biopsy

  5. Change in mean level of IL-6 in periodontitis-affected gingiva

    Time frame: The pre-treatment stage (T0) and 4 weeks ±5 days after the completion of SRP

    The mean level of IL-6 in the tissue culture medium, obtained from the same biopsy

  6. Change in mean level of IL-10 in periodontitis-affected gingiva

    Time frame: The pre-treatment stage (T0) and 4 weeks ±5 days after the completion of SRP

    The mean level of IL-10 in the tissue culture medium, obtained from the biopsy

  7. Change in mean level of TGF-β in periodontitis-affected gingiva

    Time frame: The pre-treatment stage (T0) and 4 weeks ±5 days after the completion of SRP

    The mean level of TGF-β in the tissue culture medium, obtained from the biopsy

Sponsors and collaborators

Lead sponsor

Ukrainian Medical Stomatological Academy

Other

Registry information

Official study title

Azithromycin as an Adjunct to Scaling and Root Planning Causes an Increase of CD68+, CD163+ Macrophages Density in the Gingival Tissues of Periodontitis Patients: a Randomized Controlled Short-term Clinical Trial

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Aug 18, 2022
Registry last updated
Oct 31, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.